PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 8, 2025Pulmonary Therapy2 citationsOpen Access

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center

View Full Paper
MCMarco CipolliTTTeja ThoratDRDaniela Paola Roggeri

Key Points

  • Substantial improvements in lung function were documented after treatment with ELX/TEZ/IVA, enhancing patient outcomes.
  • Study revealed positive real-world evidence, emphasizing the effectiveness of ELX/TEZ/IVA in cystic fibrosis care.
  • Retrospective study conducted at the Verona CF Center assesses treatment impact across various patient outcomes.
  • Findings support the ongoing need for effective cystic fibrosis treatments and their evaluation in real-world settings.

Abstract

Substantial improvements in lung function and reductions in HCRU were observed after treatment with ELX/TEZ/IVA in the Verona CF Center. Results contribute to the growing evidence of country-specific real-world data on the positive impact of ELX/TEZ/IVA.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cipolli et al. (2025) studied this question.

synapsesocial.com/papers/693624ad4fa91c937236c531https://doi.org/10.1007/s41030-025-00334-x
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis2024 · 10 citations
  2. 2Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-192026
  3. 3Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.2025
  4. 4SOLAR: a non-interventional study of outcomes over the long term of people with cystic fibrosis aged 6 years and older treated with ELX-TEZ-IVA using data from the French CF registry2026
  5. 5Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study2026 · 2 citations